Vivesto AB (OASMY) Research

Vivesto AB, a pharmaceutical enterprise founded in 1988 and headquartered in Solna, Sweden, is dedicated to the research, manufacturing, marketing, and distribution of medications for both human and animal oncology, primarily serving the Swedish market. Its flagship human medicine is Apealea, a paclitaxel micellar drug prescribed for the treatment of ovarian cancer. The company's human health pipeline further includes Docetaxel micellar, a unique patented formulation combining the cytotoxin docetaxel with XR-17, which is currently undergoing Phase 1b clinical trials for prostate cancer, as well as Cantrixil, another therapeutic option for ovarian cancer. In the animal health sector, Vivesto AB provides Paccal Vet, a paclitaxel formulation that utilizes its proprietary XR-17 encapsulation technology for addressing canine mastocytoma, alongside Doxophos Vet, a patented doxorubicin formulation developed to treat lymphoma. The company was previously known as Oasmia Pharmaceutical AB (publ) before adopting its current name, Vivesto AB, in March 2022.

Open Vivesto AB (OASMY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.